Drug Trial Radar · NCT04827953
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
28
Actual
Start
Sep 1, 2021
Primary completion
Apr 2025
Study completion Apr 2025
Sponsor
- Lead sponsor
- Nelum CorpIndustry
- Sponsor type
- Industry
- Collaborators
- Apices Soluciones S.L.; Agenus Inc.
- First posted
- Apr 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the first line treatment approved for this disease (gemcitabine plus nab-paclitaxel) in combination with two experimental drugs, an inhibitor of the signaling pathway of Hedgehog and an immunotherapy drug able of blocking the CTLA-4 receptor.
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
GemcitabineDrug
Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
Nab paclitaxelDrug
Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
NLM-001Drug
NLM-001 will be administered three cycles consecutively followed by two rest cycles.
ZalifrelimabDrug
Zalifrelimab administration each 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment efficacy according to responseTime frame: 17 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitario Marqués del Valdecilla
Santander, Spain
Hospital Clínico Universitario de Santiago
Santiago de Compostela, A Coruña, Spain
Hospital Universitario Virgen De La Victoria
Málaga, Andalusia, Spain
Hospital Universitario Miguel Servet
Zaragoza, Aragon, Spain
Hospital Universitario Donostia
Donostia / San Sebastian, Basque Country, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.